Gene Therapy Trials Show Vision Gains in Diabetic Patients

The clinical trial for 4D-150 demonstrated safety and improved vision for those suffering from diabetic macular edema.

Updated on Oct. 1, 2026 in Diabetes

Gene Therapy Trials Show Vision Gains in Diabetic Patients

Live Poll

Would you feel comfortable participating in a clinical trial for a new gene therapy treatment?

Results from the SPECTRA clinical trial revealed that the gene therapy 4D-150 improved visual acuity and reduced retinal thickness in patients with diabetic macular edema. Following these positive outcomes, 4DMT has initiated patient enrollment for the 4SIGHT phase 3 clinical trial.

Why it matters

Current treatment protocols for diabetic macular edema require frequent clinic visits and repeated injections, which often results in poor patient adherence. This gene therapy aims to reduce this treatment burden through a single in-office injection.

Patients receiving the 3E10 vg/eye dose showed a mean reduction of 176 µm in central subfield thickness. Additionally, 22% of these participants remained completely injection-free during the study period.

The players

4DMT

This is a clinical-stage genetic medicine company that develops therapies for severe genetic diseases.

FDA

This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.

The details

The 4D-150 treatment is administered via a single intravitreal injection, and trial patients also received three loading doses of aflibercept. The ongoing 4SIGHT phase 3 trial will further evaluate the therapy, with its primary endpoint assessing noninferiority to aflibercept at week 52 in 514 patients.

In May 2025, the FDA granted regenerative medicine advanced therapy designation to 4D-150.
The 4SIGHT clinical trial will reach its primary endpoint assessment at week 52.

The Big Picture

The granting of the FDA regenerative medicine advanced therapy designation to 4D-150 follows the agency's established intent to expedite the development of therapies for serious conditions. This classification highlights the ongoing shift toward prioritizing gene-based interventions in ophthalmic medicine.

If successful, this gene therapy could drastically reduce the number of required clinical visits and injections for patients managing diabetic macular edema. This transition from frequent, recurring treatments to a single-dose administration would significantly lower the daily treatment burden.

The takeaway

Gene therapies are moving toward providing long-term relief for chronic conditions by replacing frequent interventions with one-time treatments. Patients should consult with their retinal specialists to stay updated on the availability of emerging clinical trials for these therapies.